Teijin : Notice Regarding Completion of Transfer of Japan Sales of Type 2 Diabetes Treatments
April 31, 2021 at 08:02 pm EDT
Share
April 1, 2021
To whom it may concern
Company: Teijin Limited
Representative: Jun Suzuki, President and CEO Stock code: 3401 (First Section, Tokyo Stock Exchange)
Contact: Tomoko Torii, General Manager Investor Relations Department TEL: +81-3-3506-4395
Notice Regarding Completion of Transfer of Japan Sales of
Type 2 Diabetes Treatments
Teijin Limited ("Teijin") is pleased to announce that, today, the preconditions to the asset transfer prescribed in the asset transfer agreement that was announced in the Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina®, Liovel®, Inisync®, and Zafatek®) dated February 26, 2021 have been satisfied and the Japan sales of type 2 diabetes treatments manufactured and sold in Japan by Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President & CEO: Christophe Weber; hereinafter "Takeda") have been transferred to Teijin's subsidiary Teijin Pharma Limited (Head Office: Chiyoda-ku, Tokyo; President: Ichiro Watanabe; hereinafter "Teijin Pharma").
The sales of the following type 2 diabetes treatments (the "Products") have been transferred:
With the completion of the sales transfer today, Teijin Pharma will henceforth be selling the Products and providing and collecting relevant information in Japan. Also, to ensure stable delivery of the Products to patients, Teijin and Teijin Pharma will continue to work closely with Takeda for a smooth and efficient transfer of the manufacturing and marketing approvals concerning the Products.
- End -
Attachments
Original document
Permalink
Disclaimer
Teijin Limited published this content on 01 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 April 2021 00:01:03 UTC.
Teijin Limited is a diversified group organized around 5 areas of activity:
- manufacturing and distribution of textile products and clothes (37.6% of net sales): textile fibers, polyesters, polymers, etc.;
- production of synthetic fibers (35.5%): aramid, carbon and polyester fibers for industrial applications;
- manufacturing of care and health products (17.8%): medicines (for the treatment of metabolic, cardiovascular, bone, joint and respiratory diseases), and home care equipments (home oxygen therapy equipments and positive pressure fans);
- sale of IT products and services (6.9%);
- other (2.2%).
Net sales break down geographically as follows: Japan (58.6%), China (13.1%), Asia (6.9%), Americas (13.7%) and other (7.7%).
TEIJIN LIMITED 
